Campto (** - Brand name: Campto - Generic name: Irinotecan hydrochloride **)
Other Medications
Description
Irinotecan is used in the treatment of metastatic colorectal cancer (mCRC) as a second-line therapy after fluoropyrimidine-based regimens have failed; it has shown efficacy when combined with other agents like leucovorin and 5-fluorouracil, improving overall survival rates.
Mechanism of Action
Irinotecan is a prodrug that, after being metabolized to its active form SN-38, inhibits topoisomerase I, an enzyme involved in DNA replication and transcription; this leads to DNA damage and cell death.
Side Effects
Neutropenia; diarrea; nausea and vomiting; fatigue; alopecia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00316745
Phase 3
Suspended
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
Japan